Neurona Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neurona Therapeutics, Inc. - overview
Established
2008
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2008 by co-founder and CEO Cory R. Nicholas, Neurona Therapeutics, Inc. is a clinical-stage biotherapeutics company that focuses on the development of cell-based therapeutics and treatment devices for neurological diseases and disorders. The company raised venture funding from Ysios Capital Partners.
In April 2025, Neurona Therapeutics Inc. raised USD 102 million in venture funding from Fidelity Investments, YK Bioventures, Soleus Capital, Spur Capital Partners, Alexandria Venture Investments, Ysios Capital Partners, UC Ventures, Berkeley Frontier Fund, Willett Advisors, UCB Ventures, Euclidean Capital, LYFE Capital, Schroders Capital, Cormorant Asset Management, Viking Global Investors, The Column Group, and other unspecified investors. The company specializes in developing neural cell therapies for chronic neurological disorders. The company’s primary product, NRTX-1001, consists of inhibitory GABAergic interneurons derived from pluripotent stem cells.
NRTX-1001 is also being studied for its potential benefits in Alzheimer's disease by repairing neural activity and improving cognition. This therapy addresses drug-resistant focal epilepsy by enhancing GABAergic inhibition to reduce seizure activity. The company will use the April 2025 funding to advance its wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE).
Current Investors
The National Institutes of Health, California Institute for Regenerative Medicine, South Carolina Research Authority
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.neuronatherapeutics.com
Verticals
Manufacturing
Company Stage
Series F
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.